Spiriva’s New COPD Inhaler Competitor

Dr. Sharon Orrange
Dr. Orrange is an Associate Professor of Clinical Medicine in the Division of Geriatric, Hospitalist and General Internal Medicine at the Keck School of Medicine of USC.
Posted on

A new long acting inhaler has been approved for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The new inhaler, Tudorza Pressair, is due to come out this year and compete with Spiriva. The active ingredient in this new inhaler is aclidinium, a long-acting anticholinergic agent that was approved by the FDA for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). This means you use this inhaler daily as maintenance treatment, not as a rescue inhaler. Aclidinium is shorter-acting than tiotropium (Spiriva) and is used twice a day. Studies have shown that Tudorza is just as good as, but no better than, Spiriva.

Bring it on.

Dr O.

Tudorza Pressair cash prices will be around $230 – $250 per 30 dose inhaler, while Spiriva is currently priced at around $250 – $270 per inhaler. Spiriva is covered by most insurance plans as a Tier 2 medication, meaning a moderate copay, and it’s likely that Tudorza will have similar coverage.

Drugs featured in this story

Filed under